The purpose of this study is to look at how much of a new drug, GSK163090, binds to proteins in the brain and how much stays in the blood over a range of different doses. This study will use a medical imaging technique called Positron Emission Tomography (PET) which uses an imaging agent called \[11C\]-WAY100635.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
13
GSK Investigational Site
Toronto, Ontario, Canada
Brain receptor occupancy of GSK163090 Plasma concentrations of GSK163090
Time frame: throughout the study
Vitals signs ECGs Clinical Laboratory test results
Time frame: throughout the study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.